At Hard-Hit Gene Therapy Company Freeline, CEO Believes A Turnaround Is Possible
Readout In Hemophilia B Expected Soon
Executive Summary
Michael Parini talks to Scrip about how a new focus at the company can help it prove the value of its AAV-based gene therapy platform.